Medimaa (Macrosalb (99mtc))

Medimaa, containing the radiopharmaceutical Macrosalb, is used in nuclear medicine imaging to assess organ function and tissue distribution.

• Liver‑Spleen Scintigraphy: enables visualization of hepatic and splenic uptake for functional assessment.
• Bone Metastasis Detection: assists in identifying skeletal lesions by highlighting areas of increased radiotracer accumulation.
• Renal Function Evaluation: supports measurement of renal perfusion and filtration during dynamic imaging studies.

• Macrosalb is a technetium‑99m labeled albumin compound that, after intravenous administration, circulates in the bloodstream and is selectively taken up by the reticulo‑endothelial system and other target tissues. The emitted gamma photons are detected by a gamma camera, producing images that reflect the physiological distribution of the tracer.

Administration of Macrosalb may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Injection site pain: mild discomfort at the venipuncture site.
• Nausea: transient feeling of queasiness.
• Headache: mild to moderate headache.
• Flushing: temporary reddening of the skin.
• Warm sensation: brief feeling of warmth.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, or urticaria.
• Anaphylaxis: severe, potentially life‑threatening hypersensitivity.
• Radiation‑induced tissue injury: rare localized effects from radiation exposure.
• Hemodynamic changes: hypotension or hypertension.
• Severe nausea/vomiting: persistent gastrointestinal upset.

When using Medimaa, several precautions should be observed to ensure patient safety and maintain product integrity.

• Radiation protection: follow institutional guidelines to limit exposure to staff and patients.
• Pregnancy avoidance: avoid use in pregnant women unless clearly justified.
• Breastfeeding caution: discontinue breastfeeding for an appropriate period after administration.
• Renal impairment: assess kidney function before dosing as clearance may be reduced.
• Concomitant radiopharmaceuticals: avoid administering other radiotracers within 24 hours to prevent interference.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the kit.

Macrosalb may interact with certain medicines or substances that affect its distribution, clearance, or imaging results.

Major Interactions (Avoid)

• Other radiopharmaceuticals: concurrent use can cause image overlap and inaccurate interpretation.
• High‑dose iodine contrast agents: may alter tracer uptake and compromise scan quality.

Moderate Interactions (Monitor Closely)

• Diuretics: can modify renal clearance and affect renal imaging.
• Antihistamines: may mask mild allergic reactions.
• Calcium channel blockers: potential impact on hepatic uptake.